Vaxfectin

Vaxfectin is a second-generation cationic lipid-based suspension that adjuvants effectively both pDNA and protein-based vaccines. Vaxfectin can boost the immune response against a range of pDNA-expressed pathogenic antigens in vivo. Vaxfectin can increase IgG titers and give rise to an IL-6 dependent enhancement of the humoral immune response without altering the Th1 type immune response. Vaxfectin can be studied for vaccine formulation[1][2][3].

Product Specifications

CAS Number

[370108-99-9]

UNSPSC

12352200

Target

IFNAR; Interleukin Related; Liposome

Type

Biochemical Assay Reagents

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/vaxfectin.html

Purity

99.94

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

NCCOP(OC[C@H](OC(CC(C)CCCC(C)CCCC(C)CCCC(C)C)=O)COC(CC(C)CCCC(C)CCCC(C)CCCC(C)C)=O)(O)=O.CCCC/C=C\CCCCCCCCOCC(C[N+](C)(C)CCCN)OCCCCCCCC/C=C\CCCC.[Br-]

Molecular Formula

C81H163BrN3O10P

Molecular Weight

1450.05

References & Citations

[1]Sullivan SM, et, al. Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines. Expert Opin Drug Deliv. 2010 Dec;7 (12) :1433-46.|[2]Hartikka, J., et al., (2001) . Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine, 19 (15-16), 1911–1923.|[3]Reyes, L., et al., (2001) . Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization. Vaccine, 19 (27), 3778–3786.